Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Convergence Pharmaceuticals Ltd.

Division of Biogen Inc.
www.convergencepharma.com

Latest From Convergence Pharmaceuticals Ltd.

Appointments: Almirall, Axial, Therachon, Theranexus, Carrick and Karolinksa

This week's roundup includes Almirall's appointment of a former Sanofi employee as CEO and various other high-level appointments by Axial, Therachon, Theranexus and Karolinska.

Appointments BioPharmaceutical

Quartet Medicine Inc.

Quartet Medicine Inc.'s pipeline of novel small-molecule drugs to address chronic pain and inflammation target the tetrahydrobiopterin (BH4) synthesis pathway, a target with genetic and pharmacological links to regulating human disease at the intersection of the peripheral nervous system and the immune system. The start-up thinks its approach has the potential to provide improved efficacy without the side effects associated with existing centrally acting analgesics.

BioPharmaceutical

Biogen CEO Scangos On Alzheimer's, Multiple Sclerosis – And Pricing

George Scangos talks about the tradeoffs that drug pricing requires, and the logistical challenges that a blockbuster Alzheimer's product would create.

BioPharmaceutical Clinical Trials

Astellas, Chromocell In Pain Pact Worth $515m-plus

Astellas will pay Chromocell $15m up front and could spend more than $500m on milestone fees under a license and collaboration agreement for Nav1.7 antagonists, including lead drug candidate CC8464 and backup compounds, for the treatment of neuropathic pain and other conditions.

Orthopedics Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Biogen Inc.
  • Senior Management
  • Clive Dix, PhD, CEO
    Simon Tate, CSO
    Manjit Rahelu, VP, Bus. Dev.
  • Contact Info
  • Convergence Pharmaceuticals Ltd.
    Phone: (44) (0)1223 755 501
    Babraham Research Campus
    Maia Bldg.
    Cambridge, CB22 3AT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register